Detalhe da pesquisa
1.
PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
Blood
; 134(14): 1176-1189, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383640
2.
In vivo 18 F-fluoride-PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients.
Br J Haematol
; 200(6): 755-758, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36480438
3.
Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.
Blood
; 128(25): 2949-2959, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27733356
4.
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Blood
; 128(7): 959-70, 2016 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27307294
5.
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
J Immunol
; 197(3): 807-13, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27316683
6.
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Mol Ther
; 25(8): 1946-1958, 2017 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28506593
7.
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Br J Haematol
; 179(5): 756-771, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048129
8.
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Haematologica
; 101(5): 616-25, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26858358
9.
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Cancer Immunol Immunother
; 64(8): 951-63, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25920521
10.
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.
Haematologica
; 105(2): e80-e83, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31123033
11.
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.
Blood
; 120(3): e9-e16, 2012 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22653974
12.
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Haematologica
; 104(3): e100-e103, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190344
13.
Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2.
Sci Adv
; 10(20): eadk9076, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748792
14.
Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival.
Blood
; 117(23): 6162-71, 2011 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21471524
15.
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138.
Clin Cancer Res
; 29(20): 4219-4229, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37527004
16.
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
Nat Cancer
; 4(5): 754-773, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37237081
17.
Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
Blood
; 115(3): 601-4, 2010 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965677
18.
Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells.
iScience
; 25(1): 103605, 2022 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35005550
19.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
J Immunother Cancer
; 10(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577501
20.
N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Haematologica
; 96(11): 1653-61, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21828122